ONC COO’s routine share sale covers taxes; ownership largely unchanged

Q: Why did ONC’s President & COO sell shares on June 23 2025?

The 1,363 ADS sale was solely to cover tax withholding triggered by RSU vesting, as noted in the Form 4 footnote.

Q: How many BeOne Medicines shares does Wu Xiaobin own after the transaction?

He now holds 1,228,328 ordinary shares and 16,365 ADSs , including 4,000 ADS held indirectly via spouse.

Q: Is the June 2025 insider sale considered material for ONC investors?

No. The disposal equals roughly 1.2 % of Wu’s total holdings and is valued at about $0.35 million , below materiality thresholds.

Filing Impact

(High)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

BeOne Medicines (ONC) filed a routine Form 4 reporting a small insider transaction by President & COO Wu Xiaobin.

On 06/23/2025, Wu disposed of 1,363 American Depositary Shares at $260 per ADS (≈$0.35 million) to satisfy mandatory tax-withholding on vested RSUs. Post-sale holdings remain substantial at 1,228,328 ordinary shares plus 16,365 ADSs (4,000 held indirectly by spouse). No other changes to ownership, compensation, or governance were disclosed.

Insider Trade Summary

Net Seller: 1,363 shares ($354,380)

Net Sell 4 txns

Insider Wu Xiaobin

Role President and COO

Sold 1,363 shs ($354K)

Type	Security	Shares	Price	Value
Sale	American Depositary Shares	1,363	$260.00	$354K
holding	Ordinary Shares	--	--	--
holding	American Depositary Shares	--	--	--
holding	American Depositary Shares	--	--	--

Holdings After Transaction: American Depositary Shares — 0 shares (Direct); Ordinary Shares — 1,228,328 shares (Direct); American Depositary Shares — 4,000 shares (Indirect, By Wife)

Footnotes (1)

Each American Depositary Share represents 13 Ordinary Shares. The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 22, 2022, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events.

Form 4 Insider Transactions: What Each Field Means →

06/25/2025 - 05:08 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Wu Xiaobin

(Last)

(First)

(Middle)

C/O BEONE MEDICINES I GMBH

AESCHENGRABEN 27, 21ST FLOOR

(Street)

BASEL

4051

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
BeOne Medicines Ltd. [ ONC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	President and COO

3. Date of Earliest Transaction (Month/Day/Year)
06/23/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Ordinary Shares								1,228,328	D
American Depositary Shares⁽¹⁾								12,365	D
American Depositary Shares⁽¹⁾								4,000	I	By Wife
American Depositary Shares⁽¹⁾	06/23/2025		S⁽²⁾		1,363	D	$260	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Each American Depositary Share represents 13 Ordinary Shares.

2. The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 22, 2022, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events.

Remarks:

	/s/ Qing Nian, as Attorney-in-Fact	06/25/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

Why did ONC’s President & COO sell shares on June 23 2025?

The 1,363 ADS sale was solely to cover tax withholding triggered by RSU vesting, as noted in the Form 4 footnote.

How many BeOne Medicines shares does Wu Xiaobin own after the transaction?

He now holds 1,228,328 ordinary shares and 16,365 ADSs, including 4,000 ADS held indirectly via spouse.

Is the June 2025 insider sale considered material for ONC investors?

No. The disposal equals roughly 1.2 % of Wu’s total holdings and is valued at about $0.35 million, below materiality thresholds.

Did the Form 4 reveal any new governance or compensation changes at ONC?

No. The filing only details the routine tax-related share sale; no governance or compensation changes were reported.